Wenda Pharma’s BET inhibitor gets breakthrough designation in China for NUT carcinoma

Edited by Robert McTiernan··3 min read

China’s first targeted therapy candidate for NUT carcinoma entered an accelerated regulatory pathway, with interim Phase II data supporting an objective response rate of 45% in the thoracic subgroup. Zhejiang Wenda Pharmaceutical Technology Co., Ltd. (Wenda Pharma), a biotech headquartered in Shaoxing, China, announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to NHWD-870 HCl, an oral small-molecule bromodomain and extra-terminal (BET) inhibitor, for the treatment of advanced thoracic midline (NUT) carcinoma in patients who have failed prior chemotherapy.

The NMPA Breakthrough Therapy Designation enables closer regulatory engagement during development, rolling submission of application modules, and priority review resource allocation — mechanisms that can shorten the interval between trial completion and potential approval in China. No prior expedited designations from the US FDA or EMA have been disclosed for NHWD-870.

The designation was granted on the basis of interim data from a multicenter, open-label, single-arm Phase II study (NCT06527300) enrolling adults and adolescents with advanced NUT carcinoma. As of the December 27, 2025 data cutoff, 40 subjects were evaluable across lesion sites. In the pre-specified cohort of 20 patients with advanced thoracic NUT carcinoma — the population covered by the designation — the objective response rate (ORR) was 45%. Median overall survival (mOS) was 9.33 months in both the thoracic subgroup and the full 40-patient evaluable population. The company characterized the drug as generally well tolerated in preliminary safety reporting; specific rates for grade 3 or higher adverse events were not disclosed. No p-values were reported, consistent with the single-arm design of the study.

The company has not disclosed progression-free survival, duration of response, or a full safety profile. The comparative survival claim — that 9.33 months represents an extension relative to standard chemotherapy — appears to rest on a historical rather than randomized comparison, as no control arm is described in the study design or the announcement.

The AllSci BriefSystematic R&D and deal news. Daily.

Research context

NUT carcinoma, defined by rearrangement of the NUTM1 gene, is a poorly differentiated carcinoma with a median age of onset of 23.6 years and a reported median survival of approximately 6.5 months. It arises most commonly in the thorax, head, and neck. Because its clinical presentation overlaps with other poorly differentiated malignancies, rates of misdiagnosis are high, and most patients present at an advanced stage. No targeted therapy has received regulatory approval globally for this indication, leaving cytotoxic chemotherapy as the standard of care despite limited efficacy.

The BET protein family — comprising BRD2, BRD3, BRD4, and BRDT — regulates transcription through bromodomain-mediated recognition of acetylated histones. In NUT carcinoma, the NUTM1 fusion protein, most commonly involving BRD4, drives oncogenic transcription through constitutive BET-mediated activity. BET inhibition has therefore been a mechanistically rational strategy in this disease for over a decade, though clinical translation has been constrained by tolerability issues and limited efficacy in broader oncology populations.

The only BET inhibitor to have reached late-stage evaluation in NUT carcinoma prior to NHWD-870 is ZEN-3694 (Zenith Epigenetics), which has been studied in combination regimens. Molibresib (GSK525762, GlaxoSmithKline) was evaluated in a Phase II basket study that included NUT carcinoma patients and reported an ORR of 21% in that subgroup, with responses described as short-lived in most cases. Wenda positions NHWD-870 as a potential first-in-class oral small-molecule BET inhibitor to reach this regulatory threshold.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/